HCA HCA Healthcare, Inc.
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.…
Industry Peers
Medical Care FacilitiesKey Statistics
About HCA Healthcare (NYSE: HCA)
›
HCA Healthcare (NYSE: HCA) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 230,000 employees.
The shares were at 460.24 USD on 19 November 2026, down 2.3% over 52 weeks. Its 52-week range is 354.00 USD to 556.52 USD: the price is 17.3% below the high and 30.0% above the low.
At a market capitalisation of 96.16B USD, it trades at 15.3 times trailing earnings and 14.7 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.7, a discount of 36% for HCA. It pays a dividend yielding 0.66% (it pays out 10% of its earnings), against a median of 0.84% among the dividend payers in that peer group.
HCA Healthcare reports return on equity of -112.6%, an operating margin of 15.3% and revenue up 3.6% year over year.
Its debt exceeds its cash by 51.41B USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 22 analysts cover the stock, with an average rating of Buy; their mean price target of 485.68 USD is 5.5% above the current price. The next earnings report is expected on 26 January 2027.